NANatali Abeywickrama-Samarakoon

Natali Abeywickrama-Samarakoon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Natali Abeywickrama-Samarakoon has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Réplication du génome du virus de l’hépatite delta : un rôle pour la petite protéine delta S-HDAg

    by Natali Abeywickrama-Samarakoon, Jean-Claude Cortay, Camille Sureau, Dulce Alfaiate, Massimo Levrero, Paul Dény

    Le virus de l’hépatite delta, aussi appelé virus de l’hépatite D ou HDV, est un agent viral défectif à ARN de polarité négative. Il se réplique dans les cellules de mammifère et infecte l’homme. Son génome est un petit ARN circulaire monocaténaire d’environ 1 680 nucléotides. Pour se propager, HDV a cependant besoin d’un autre virus, le virus de l’hépatite B (HBV), qui lui fournit les protéines d’enveloppe nécessaires à l’assemblage de ses virions et à la propagation de l’infection. Les manifestations cliniques graves de l’infection combinée HBV-HDV vont des formes aiguës d’hépatites fulminantes aux formes chroniques de fibroses du foie (cirrhose), qui peuvent conduire à un carcinome hépatocellulaire. Une originalité de l’HDV repose sur la ressemblance de son génome avec celui des viroïdes, des agents infectieux des plantes constitués de petits ARN circulaires non encapsidés. Dépourvu de toute activité réplicase virale, l’HDV doit utiliser l’activité ARN polymérase-ADN dépendante de la cellule qu’il infecte pour répliquer son ARN génomique. Comment dès lors, cette réplication se réalise ? Nous aborderons dans cette revue les principales étapes de la transcription et de la réplication de ces ARN viraux. Hepatitis delta virus (HDV) is a mammalian defective virus. Its genome is a small single-stranded circular RNA of approximately 1,680 nucleotides. To spread, HDV relies on hepatitis B virus envelope proteins that are needed for viral particle assembly and egress. Severe clinical features of HBV-HDV infection include acute fulminant hepatitis and chronic liver fibrosis leading to cirrhosis and hepatocellular carcinoma. One uniqueness of HDV relies on its genome similarity to viroids, small plant infectious uncoated RNAs. Devoid of viral replicase activity, HDV has to use host DNA-dependant RNA Pol II to replicate its genomic RNA. Thus, one can ask how does this replication occur? We describe first here the major steps of the viral RNA transcription and replication and then we detail the role of the Small HD protein in these processes, especially with regard to the Pol II recruitment.


  • Open Access

    Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults

    by Narcisse Patrice Komas, Sumantra Ghosh, Mariama Abdou-Chekaraou, Pierre Pradat, Nasser Al Hawajri, Alexandre Manirakiza, Gina Laure Laghoe, Claudine Bekondi, Ségolène Brichler, Jean-Omer Ouavéné, et al.

    Hepatitis delta virus (HDV) increases morbidity in Hepatitis B virus (HBV)-infected patients. In the mid-eighties, an outbreak of HDV fulminant hepatitis (FH) in the Central African Republic (CAR) killed 88% of patients hospitalized in Bangui. We evaluated infections with HBV and HDV among students and pregnant women, 25 years after the fulminant hepatitis (FH) outbreak to determine (i) the prevalence of HBV and HDV infection in this population, (ii) the clinical risk factors for HBV and/or HDV infections, and (iii) to characterize and compare the strains from the FH outbreak in the 1980s to the 2010 HBV–HDV strains. We performed a cross sectional study with historical comparison on FH-stored samples (n = 179) from 159 patients and dried blood-spots from volunteer students and pregnant women groups (n = 2172). We analyzed risk factors potentially associated with HBV and HDV. Previous HBV infection (presence of anti-HBc) occurred in 345/1290 students (26.7%) and 186/870 pregnant women (21.4%)(p = 0.005), including 110 students (8.8%) and 71 pregnant women (8.2%), who were also HBsAg-positive (p = 0.824). HDV infection occurred more frequently in pregnant women (n = 13; 18.8%) than students (n = 6; 5.4%) (p = 0.010). Infection in childhood was probably the main HBV risk factor. The risk factors for HDV infection were age (p = 0.040), transfusion (p = 0.039), and a tendency for tattooing (p = 0.055) and absence of condom use (p = 0.049). HBV-E and HDV-1 were highly prevalent during both the FH outbreak and the 2010 screening project. For historical samples, due to storage conditions and despite several attempts, we could only obtain partial HDV amplification representing 25% of the full-length genome. The HDV-1 mid-eighties FH-strains did not form a specific clade and were affiliated to two different HDV-1 African subgenotypes, one of which also includes the 2010 HDV-1 strains. In the Central African Republic, these findings indicate a high prevalence of previous and current HBV-E and HDV-1 infections both in the mid-eighties fulminant hepatitis outbreak and among asymptomatic young adults in 2010, and reinforce the need for universal HBV vaccination and the prevention of HDV transmission among HBsAg-positive patients through blood or sexual routes. In the Central African Republic (CAR), due to 20 years of conflict, the health system has been disorganized. This could contribute to maintenance of high transmission levels of Hepatitis B Virus (HBV) and its satellite Hepatitis Delta Virus (HDV). This work studies the evolution of both infections 25 years after a fulminant hepatitis (FH) outbreak occurring in the mid-1980s associated with HDV superinfection. In young asymptomatic adults, the results show that both HBV and HDV were still actively circulating in CAR in 2010. Indeed, more than one third of HBV-infected individuals were chronic HBV carriers. Furthermore, HDV infection could be spreading among 10% of them through blood and sexual transmission. The past FH outbreak and contemporary infections were both associated with heterogeneous HDV-1 strains, combined with HBV-E. Vaccination against HBV was uncommon among pregnant women and students, even among medical students. The study constitutes warning signals to help CAR health-care reconstruction and underlines the importance of HBV vaccination. The high level of HBV infection creates a background for HDV superinfection. Neonatal HBV vaccination is needed, together with vaccination of unprotected populations. Awareness of health authorities as well as the general public would help reduce HBV and HDV infections.


  • HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes

    by Dulce Alfaiate, Julie Lucifora, Natali Abeywickrama-Samarakoon, Maud Michelet, Barbara Testoni, Jean-Claude Cortay, Camille Sureau, Fabien Zoulim, Paul Dény, David Durantel


  • The hepatitis D satellite virus of hepatitis B virus

    by Natali Abeywickrama-Samarakoon, Jean-Claude Cortay, Paul Dény

    Purpose of review To highlight new concepts and therapeutic approaches concerning hepatitis D virus (HDV) infection. Recent findings Common receptor for hepatitis B virus (HBV) and HDV has been elucidated, deciphering of HDV replication is still in progress, preliminary results of phase II proof-of-concept clinical assays for entry inhibitors and cellular farnesyl transferase inhibitors are now available. Summary Hepatitis D infection remains a severe acute and chronic liver illness with the only currently approved therapy (Peg-alpha IFN) achieving disappointingly low rates of sustained viral response and clinical improvement. Both sodium taurocolate cotransporting polypeptide and heparan sulphate glypican 5 are important for viral adsorption. Preliminary results of 6 months treatment with a subcutaneous HBV PreS1-derived myristoyled peptide as an entry inhibitor indicates an encouraging short-term response with low side-effects. In addition, the short-term use of oral farnesyl transferase inhibitors induces a log(10) reduction of viral RNA in almost all treated patients, but is associated with gastrointestinal upset and weight loss (especially using 200 mg/day). Encouraging results are being reported using intravenous phosphorothioate nucleic acid polymers both in terms of HBV surface antigens (HBsAg) and HDV-RNA decline; interestingly, in some patients with a strong HBsAg decline, the appearance of anti-hepatitis Bs antibodies might suggest clinical end-point improvement.